Search Results 211-220 of 15935 for SC
The purpose of this study is to demonstrate pharmacokinetic non-inferiority for nivolumab + relatlimab FDC SC (fixed-dose combination for subcutaneous ...
... SC, Rabinovici GD, LEADS Consortium//PREVENT-AD Research Group//Alzheimer's Disease Neuroimaging Initiative. Calibration of multisite raters for prospective ...
Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and ...
... SC, Habermann EB, Bosch W, Cowart JB, Yao X. Safety in a hybrid hospital-at-home program versus traditional inpatient care: A pragmatic randomized ...
2014.08.019. Fiesel FC, Caulfield TR, Moussaud-Lamodière EL, Ogaki K, Dourado DF, Flores SC, Ross OA, Springer W. Structural ...
The purpose of this study is to evaluate effects on proteinuria and glomerular filtration rate of sibeprenlimab 400 mg subcutaneously (s.c.) Q 4 weeks in ...
The team has developed a recombinant adeno-associated virus (AAV) carrying the IL-1Ra cDNA (sc-rAAV2.5IL-1Ra) as a therapeutic for injection into joints ...
Camilleri, Michael M.D., D.Sc. camilleri.michael@mayo.edu; Professor of Medicine; Professor of Pharmacology; Professor of Physiology; Publications · Cipriani ...
A patient of Carolinas Hospital System in Florence, South Carolina, part of the Mayo Clinic Care Network, Andrew had a consult with oncologist Ziad Skaff, M.D., ...
Amplify expertise. Collaborate with the most trusted leader in health care to amplify your clinical, educational and research expertise. · More care close to ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.